• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Epix appoints marketing VP

Article

MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in

MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in phase II clinical trials for peripheral vascular disease, coronary artery disease, and breast cancer (SCAN 1/14/98). Mayer joins Cambridge, MA-based Epix from a position as worldwide marketing manager at pharmaceutical firm Chiron Diagnostics. He has also been employed by Abbott Diagnostics.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.